NEW YORK, Feb. 12, 2019 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss, you can request that the Court appoint you as lead plaintiff.  Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Danske Bank A/S (OTCMKT: DNKEY) 
Class Period: January 9, 2014 - October 23, 2018
Lead Plaintiff Deadline: March 11, 2019
For more info: www.bgandg.com/dnkey

The Complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements and/or failed to disclose that: (1) Danske Bank’s Estonian branch was facilitating money laundering through at least March 2016; (2) that a whistleblower had reported the Estonian money laundering to the Company in 2013; (3) that Denmark’s Financial Supervisory Authority (the “DFSA”) had been investigating the Estonian money laundering since 2014; (4) that Danske Bank had concealed the results of its own internal investigation from the DFSA, further exposing it to regulatory action and fines; (5) that Danske Bank had been overstating its historical profits by including the profits derived from its illicit Estonian operations; and (6) that Danske Bank lacked effective internal and reporting controls.

AxoGen, Inc. (NASDAQ: AXGN)
Class Period: securities pursuant and/or traceable to (1) the Company’s registration statement and prospectus (collectively, the “November 2017 Registration Statement”) issued in connection with its November 2017 secondary public offering (“November SPO”); and/or (2) the Company’s registration statement and prospectus (collectively, the “May 2018 Registration Statement”) issued in connection with the Company’s May 2018 secondary public offering (“May SPO”); and/or (3) between August 7, 2017 and December 18, 2018, inclusive (the “Class Period”).
Lead Plaintiff Deadline: March 11, 2019
For more info: www.bgandg.com/axgn

The Complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements and/or failed to disclose that: (1) AxoGen aggressively increased prices to mask lower sales; (2) AxoGen’s pricing alienated customers and threatened the Company’s future growth; (3) ambulatory surgery centers form a significant part of the market for the Company’s products; (4) such centers were especially sensitive to price increases; (5) the Company was dependent on a small number of surgeons whom the Company paid to generate sales; (6) AxoGen’s consignment model for inventory was reasonably likely to lead to channel stuffing; (7) the Company offered purchase incentives to sales representatives to encourage channel stuffing; (8) the Company’s sales representatives were encouraged to backdate revenue to artificially inflate metrics; (9) the Company lacked adequate internal controls to prevent such channel stuffing and backdating of revenue; (10) the Company’s key operating metrics, such as number of active accounts, were overstated; and (11) consequently, Defendants’ positive statements about the Company’s business, operations, and prospects, were materially misleading and/or lacked a reasonable basis.

Wayfair Inc. (NYSE: W)
Class Period: August 2, 2018 - October 31, 2018
Lead Plaintiff Deadline: March 11, 2019
For more info: www.bgandg.com/w

The Complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements and/or failed to disclose material adverse information, including that Wayfair was experiencing significant drop in demand for its online product offerings and was increasing its advertising to boost sales. As a result of defendants’ false statements and/or omissions, Wayfair stock was artificially trading at more than $149 per share during the Class Period. While the stock was trading at this high price, some of its senior executives and directors cashed in and sold over $87.75 million of their personally held shares.

Markel Corporation (NYSE: MKL) 
Class Period:
July 26, 2017 - December 6, 2018
Lead Plaintiff Deadline: March 12, 2019
For more info: www.bgandg.com/mkl

The Complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements and/or failed to disclose that: (1) Markel’s subsidiaries did not appropriately record loss reserves; (2) as a result, the loss reserves would need to be adjusted and/or restated; (3) these misleading accounting practices would lead to regulatory scrutiny and financial loss to investors; and (4) consequently, Defendants’ positive statements about the Company’s business, operations, and prospects, were materially misleading and/or lacked a reasonable basis.

Contact:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com